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ABSTRACT
Objectives: To assess the efficacy and safety of steroid
injections for patients with tendonitis of the shoulder or
elbow.
Methods: A systematic review of the literature using
PubMed, EMBASE, the Cochrane library and manual
searches was performed until April 2008. All randomised
controlled trials (RCTs) reporting the efficacy on pain or
functional disability, and/or the safety of steroid injections,
versus placebo, non-steroidal anti-inflammatory drugs
(NSAIDs) or physiotherapy in patients with tendonitis
were selected. Pooled effect size (ES) was calculated by
meta-analysis using the Mantel–Haenszel method.
Results: In all, 20 RCTs were analysed (744 patients
treated by injections and 987 patients treated by controls;
618 shoulders and 1113 elbows). The pooled analysis
indicated only short-term effectiveness of steroids versus
the pooled controls for pain and function (eg, pain at week
1–3 ES=1.18 (95% CI 0.27 to 2.09), pain at week 4–8
ES=1.30 (95% CI 0.55 to 2.04), pain at week 12–24
ES=20.38 (95% CI 20.85 to 0.08) and pain at week 48
ES=0.07 (95% CI 20.60 to 0.75)). Sensitivity analyses
indicated similar results whatever the localisation, type of
steroid and type of comparator except for NSAIDs: steroid
injections were not significantly better than NSAIDs in the
short-term. Steroid injections appeared more effective
than pooled other treatments in acute or subacute
tendonitis. The main side effects were transient pain after
injection (10.7% of corticosteroid injections) and skin
modification (4.0%).
Conclusions: Steroid injections are well tolerated and
more effective for tendonitis in the short-term than pooled
other treatments, though similar to NSAIDs. No long-term
benefit was shown.
Tendon lesions represent a large proportion of
rheumatic issues resulting in pain and disability,
and absence from work.
1 The shoulder and elbow
are the most frequent localisations.
23 The most
common type of tendon lesion is tendinosis, which
is an intratendinous degeneration and is the basis
of epicondylitis, rotator cuff tendonitis or sub-
acromial impingement.
45The physiopathology of
these disorders is different from adhesive capsulitis
or full thickness rotator cuff tear.
4 Tendon lesions
are a therapeutic challenge for the general practi-
tioner and the rheumatologist. There are a great
variety of potential treatments, surgical interven-
tion being the most radical. In usual practice, pain-
relieving medications, non-steroidal anti-inflam-
matory drugs (NSAIDs), steroid injections and
physical therapy are the most frequent options.
2
Although local steroid injections are one of the
most common treatments, there is no strong
evidence to support their use
6 and they have
potential adverse effects.
7 The optimum timing of
steroid injections is also still unclear. Because of
conflicting results, two meta-analyses were con-
ducted several years ago, one in 1996
8 and one in
2002 by the Cochrane group;
6 however, this second
analysis included various shoulder disorders (rota-
tor cuff disease, adhesive capsulitis, full thickness
rotator cuff tear and mixed diagnoses). Moreover
the conclusion was not clear cut. In 2002, Smidt
et al
9 concluded that although the available
evidence shows superior short-term effects of
corticosteroid injections for lateral epicondylitis,
it was not possible to draw firm conclusions on the
effectiveness of injections, due to the lack of high
quality studies. Therefore it appeared important to
perform a new systematic review, including
diagnostic considerations and recent trials.
The objective of the present study was to assess
the efficacy on pain and functional disability, and
to assess the safety of, steroid injections for
patients with tendonitis of the shoulder and elbow
in published randomised controlled trials (RCTs).
The clinical question considered was whether or
not steroid injections are effective compared with
other commonly used treatments (‘‘wait and see’’,
NSAIDs, physiotherapy) or placebo in terms of
improvement of pain and functional ability in
tendinosis (ie, epicondylitis, rotator cuff tendonitis
or subacromial impingement).
METHODS
This meta-analysis was conducted according to the
Cochrane Collaboration guidelines.
10
Study selection
A systematic literature search was performed in
PubMed Medline, EMBASE and Cochrane library
databases up to April 2008 without limitation of
years of publication or journal, using the following
keywords: ((‘‘shoulder pain’’[MeSH] OR ‘‘shoulder
pain’’[All Fields]) OR (‘‘shoulder joint’’[MeSH
Terms] OR ‘‘shoulder joint’’[All Fields]) OR
(‘‘rotator cuff’’[MeSH Terms] OR ‘‘rotator
cuff’’[All Fields]) OR (‘‘shoulder impingement
syndrome’’[MeSH Terms] OR ‘‘shoulder impinge-
ment syndrome’’[All Fields] OR ‘‘subacromial
impingement syndrome’’[All Fields]) OR (epicondy-
litis [All Fields] OR ‘‘tennis elbow’’[MeSH Terms]
OR ‘‘tennis elbow’’[All Fields]) OR (‘‘tendon
injuries’’[MeSH Terms] OR ‘‘tendon injuries’’[All
Fields])) AND ((‘‘steroids’’[MeSH Terms] OR
‘‘steroids’’[All Fields] OR ‘‘steroid’’[All Fields]) OR
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Fields] OR ‘‘glucocorticoids’’[Pharmacological Action])). The
limits were English or French language and clinical trial or RCT.
In addition, reference lists of the papers initially detected were
manually searched to identify additional relevant reports.
The trials were initially selected on the basis of their titles and
abstract, then on the full texts. The inclusion criteria were all
RCTs reporting the efficacy on pain and/or function, and/or the
safety of steroid injections versus placebo, ‘‘wait and see’’,
NSAIDs or physiotherapy in patients with epicondylitis, rotator
cuff tendonitis or subacromial impingement. Articles reporting
no interpretable results (data required included mean (SD)) for
any of the three outcome measures (pain, function and safety)
were not analysed.
Data collection
One investigator (CGV) selected the articles and collected the
data using a predetermined form. The following methodological
features were collected: blinding, intention to treat analysis or
not and number of participants who completed follow-up. The
Jadad scale was applied,
11 which contains two questions for
randomisation and masking and one question evaluating the
reporting of withdrawals and dropouts. Each question entails a
yes or no response option. In total, 5 points can be awarded,
with higher scores indicating higher quality. For each trial,
demographic characteristics (sex, mean age), tendinosis features
and duration, type of steroid (with doses and number of
injections), type of comparator and duration of follow-up were
collected. Acute/subacute and chronic disease were defined as
having a symptom duration of ,12 weeks versus >12 weeks,
respectively. Pain intensity was extracted from the studies, as
available, by a 100 mm visual analogue scale (VAS), the Patient
Related Forearm Evaluation Questionnaire (PREFQ)-pain,
12 or
other pain scores; physical function was extracted, as available,
by the Disabilities of the Arm, Shoulder and Hand (DASH)
score,
13 the PREFQ-function,
12 the total constant score,
14 the
limitation of function 10-point Likert scale,
15 or the function
scores (0–3 scale,
16 0–5 scale).
17 Pain intensity and physical
function assessed by different scores according to different
studies were transformed linearly to fit the range 0–100, in
which 0 was the best situation and 100 the worst. Efficacy was
assessed by the change in overall pain intensity and/or physical
function status between baseline and week 1 to 3, week 4 to 8,
week 12 to 24 and week 48 (as available according to the
studies) in steroid injection and control groups.
In order to evaluate safety, data were extracted from each
study in active and control groups regarding the number and the
type of all adverse events reported.
Statistical analysis
In each trial the effect size (ES) or the standardised response
mean (SRM) were determined to assess the magnitude of
treatment effect. The ES is calculated as the ratio of the
treatment effect (mean differences in treatment group minus
differences in control group) to the pooled standard deviation of
these differences.
18 Improvement (eg, lower pain VAS) was
considered as a positive change. This calculation entails the use
of means for baseline and final data with a measure of
variability such as SD. Every effort was made to calculate the
ES in all studies. If the SD was given in only one group it was
used as baseline SD for both groups. However, if no measure of
variability was given the ES could not be extrapolated and we
calculated the SRM (mean change divided by SD of the change)
when available. By convention, an ES ,0.2 is usually considered
as trivial; 0.2–0.5 as small; 0.5–0.8 as moderate; 0.8–1.2 as
important and .1.2 as very important.
19 SRM values .0.8 are
considered as large. Pooled ES and pooled SRM were calculated
by meta-analysis, using the Mantel–Haenszel method. The
RevMan V.4.2 statistical software (Review Manager,
Copenhagen, Denmark) was used. Primary analyses examined
pooled ES and pooled SRM of steroid injections versus controls
for pain intensity and physical function. Sensitivity analyses
were calculated within subgroups of studies decided a priori
(joint involved, duration of pain, type of steroid and type of
comparator) to assess the robustness of the main conclusions.
Statistical heterogeneity was tested by Q test (x
2).
20 All meta-
analyses were carried out with use of random effects model in
case of significant heterogeneity. The number needed to harm
(NNH) was used to assess steroid injections safety. Harm was
primarily defined by the occurrence of one or more adverse
events. The NNH is the number of patients that should be
treated to observe the occurrence of one extra adverse event in
the treatment group compared to the control group. The
advantage of the NNH is that it reflects an absolute risk
increase, and because it is related to the control event rate, it
reflects the true baseline or underlying risk of the study
population.
21 For rational decision making in daily clinical
practice, absolute measures such as NNH may be more
meaningful than relative measures.
22 Because of the large and
non-significant confidence intervals around the steroid injection
adverse event rates, confidence intervals were not reported for
the NNH, as proposed by McQuay and Moore.
23
RESULTS
Literature search results and trials characteristics
Initially, 218 potentially relevant articles were screened. From
them, 199 were excluded. Finally, after manually searching the
reference lists, 20 randomised trials were included: 16 for
efficacy and 19 for safety (selection process shown in
Supplementary material). Thus, this systematic review included
1731 patients; 744 (43.0%) patients treated by injection and 987
(57.0%) patients treated by other treatments (n=570) or
placebo (n=417). A total of 618 (35.7%) presented with a
shoulder lesion and 1113 (64.3%) with an elbow lesion. The
mean (SD) age of these patients was 47.6 (4.8) years and 694
(38%) were women. Patient characteristics are detailed in table 1
and trial characteristics in the Supplementary material.
The methodological quality was correct: the mean (SD) Jadad
score was 3.1 (0.9) (range 1–5). In all, 13 (65%) trials performed
intention to treat (ITT) analyses (see Supplementary material).
Of the 16 trials for efficacy, 9 included a flowchart or described
precisely the patient selection process and outcome, 14 used a
concealed random allocation and 11 presented differences in
change with confidence intervals, 2 with interquartile range and
2 with standard error of the mean.
Efficacy of steroid injections
Of the 20 RCTs analysed, 16 provided the required data to
calculate the efficacy on pain intensity for 511 participants who
received steroid injections and for 763 who received a
comparator. Eight studies concerned shoulder tendinosis and
eight epicondylitis. The data on function were extracted from 7
RCTs: 4 concerning the shoulder and 3 concerning the elbow (a
total of 614 patients). The characteristics of these trials are
summarised in the Supplementary material and the ES or SRM
for pain intensity and physical function at different end points
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detailed in table 2.
The pooled analysis is shown table 3, and indicated short-
term effectiveness (1–3 weeks and 4–8 weeks) of steroids (figs 1
and 2). At longer-term follow-up no difference for pain could be
detected, and steroid injections appeared less effective particu-
larly on functional disability than pooled other treatments.
Heterogeneity
The heterogeneity was substantial for pain, and to a lesser
extent for function, at week 1–3 and at week 4–8 (for example
pain ES: Q=99.25 for 6 degrees of freedom; p,0.001 and
Q=197.35 for 10 degrees of freedom; p,0.001). The other
results were homogeneous.
Sensitivity analyses: location and steroid used
In the assessment of heterogeneity, sensitivity analyses showed
no changes in the conclusions according to the localisation, or
the type of steroid (data not shown).
Sensitivity analyses: type of comparator
Steroid injections were more efficient in the short-term (week 1
to 3 and week 4 to 8) than different comparators (table 3).
However the pooled ES versus NSAIDs were not significant in
the short-term; long-term results were significant but are issued
from a single study.
16 Moreover steroid injection was shown to
have a more important benefit on pain compared to placebo
than to physiotherapy: pain at week 4–8 versus placebo
ES=1.67 (95% confidence interval (CI) 0.56 to 2.78) versus
pain at week 4–8 versus physiotherapy ES=0.51 (95% CI 0.19
to 0.84) (p,0.001).
Sensitivity analyses: disease duration
This meta-analysis suggested that steroid injections are more
effective in acute or subacute tendonitis (duration of symptoms
below 12 weeks) than in chronic disease: pain at week 1–3
SRM=3.35 (95% CI 1.63 to 5.08) versus 0.37 (95% CI 20.17 to
0.92) (p,0.001).
Safety of steroid injections
In all, 19 studies (no. of patients=1754) provided suitable data
to assess corticosteroid injection safety. The main side effects
were transient pain after injection (10.7% of corticosteroid
injection) and skin atrophy or depigmentation (4.0%). There
were no treatment discontinuations for toxicity. The NNH for
steroid injection versus other commonly used treatments was
26 (ie, 26 patients would need to be treated to observe the
occurrence of 1 extra adverse event in the injection group)
compared to all the comparators, and versus placebo it was 9;
however, the confidence intervals were not significant. The
NNH values versus each comparator and calculated for each
adverse event are provided in table 4.
DISCUSSION
This meta-analysis indicated short-term effectiveness (1–3
weeks and 4–8 weeks) of steroid injections in shoulder and
elbow tendinosis on pain and functional disability, but at
longer-term follow-up no difference for pain could be detected
and steroid injections appeared less effective for function than
pooled other treatments. Compared to NSAIDs however,
steroid injections did not appear statistically more efficacious
in the short term.
There is little consensus on the optimum timing of
corticosteroid injections in tendonitis, relative to the symptom
duration. Some experts advocate injections when the patient
does not respond to a certain period of rest (2 or 3 months),
34
whereas others argue that injectable steroids should be deferred
as long as possible.
35 However, this meta-analysis has shown
that steroid injections are more effective in acute or subacute
tendonitis (duration of symptoms below 12 weeks) than in
chronic disease. Therefore our results indicate that the optimum
timing for steroid injections may be in the early weeks of
tendonitis symptoms.
Despite the high level of interest in the aetiologies, diagnosis
and treatment of tendonitis in the literature, there are relatively
few randomised controlled trials and the outcomes used are
heterogeneous. Physical function was rarely assessed by the
same score in different studies. In some studies the ES or the
SRM could not be extrapolated either due to lack of data or to
inappropriate outcomes (eg, qualitative evaluation). Another
limitation of this review is possible publication bias (ie, negative
trials are often unpublished, which may have overestimated the
beneficial effect of corticosteroid injections).
Several reviews on the utility of steroid injections in shoulder
pain have been performed and conflicting results found, but the
studies analysed assessed a wide variety of conditions and
disorders (including frozen shoulder) and there was often no
pooling of results.
36 37 A Cochrane review found that subacro-
mial steroid injection was effective in improving the range of
Table 1 Characteristics of patients with tendonitis included in a meta-analysis of randomised controlled
trials of steroid injections for shoulder and elbow tendonitis
All patients
Injection group
(steroids) Control group
Number of patients 1731 744 987
Mean (SD) age, years 47.5 (4.9) 48.2 (5.2) 47.3 (5.8)
Female sex, n (%) 659 (38) NA NA
Number of patients with shoulder lesion: rotator cuff tendonitis
and subacromial impingement (%)
618 (33.9) 315 303
Acute 2253 (40.9) 2122 2131
Chronic 2245 (39.6) 2103 2142
Heterogeneous 2120 (19.4) 290 2 30
Number of patients with elbow lesion: epicondylitis (%) 1113 (64.3) 429 684
Acute 2513 (46.1) 2168 2345
Chronic 2483 (43.4) 2208 2275
Heterogeneous 2117 (10.5) 253 264
Acute: ,12-week symptom duration; chronic: >12-week symptom duration, heterogeneous: variable symptom duration.
NA, not available.
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Ann Rheum Dis 2009;68:1843–1849. doi:10.1136/ard.2008.099572 1845Table 2 Effect size and standardised response mean of controlled trials comparing steroid injections with placebo or other comparator for pain
intensity and physical function in patients with tendonitis
Reference Comparator Outcome measure Week 1–3 Week 4–8 Week 12–24 Week 48
Vecchio et al
(1993)
24
Placebo Pain VAS SRM=1.16 (0.58 to
1.72)
SRM=0.90 (0.34 to
1.44)
SRM=0.00 (20.53 to
0.53)
NA
Adebajo et al
(1990)
16
Placebo Pain VAS NA SRM=1.09 (0.40 to
1.73)
NA NA
Limitation of function
(0–3 scale)
NA SRM=3.22 (2.23 to
4.08)
NA NA
Oral diclofenac Pain VAS NA SRM=0.43 (20.21 to
1.05)
NA NA
Limitation of function
(0–3 scale)
NA SRM=0.00 (20.62 to
0.62)
NA NA
White et al (1986)
25 Indomethacine Pain VAS NA ES=20.21 (20.83 to
0.41)
NA NA
Berry et al (1980)
26 Placebo Pain VAS ES=20.17 (20.96 to
0.64)
ES=20.68 (21.48 to
0.16)
NA NA
Physiotherapy Pain VAS ES=0.14 (20.67 to
0.93)
ES=0.19 (20.62 to 0.99) NA NA
Petri et al (1987)
17 Placebo Pain score SRM=0.45 (20.12 to
1.00)
SRM=0.66 (0.08 to 1.22) NA NA
Limitation of function
(0–5 scale)
SRM=0.64 (0.06 to
1.19)
SRM=0.39 (20.17 to
0.95)
NA NA
Naproxen Pain score SRM=0.11 (20.45 to
0.66)
SRM=0.12 (20.43 to
0.68)
NA NA
Limitation of function
(0–5 scale)
SRM=0.10 (20.46 to
0.65)
SRM=20.05 (20.60 to
0.51)
NA NA
Alvarez et al
(2005)
13
Placebo Pain VAS ES=0.26 (20.24 to
0.76)
ES=20.29 (20.78 to
0.22)
ES=20.41 (20.93 to
0.11)
NA
DASH ES=0.19 (20.31 to
0.69)
ES=20.09 (20.58 to
0.41)
ES=20.27 (20.76 to
0.24)
NA
McInerney et al
(2003)
27
Wait and see Pain VAS NA NA ES=0.10 (20.31 to 0.52) NA
Akgu ¨n et al (2004)
14 Placebo Pain VAS NA ES=0.71 (20.02 to 1.40) ES=0.28 (20.42 to 0.97) NA
Total Constant score NA ES=0.35 (20.36 to 1.04) ES=0.09 (20.61 to 0.78) NA
Lewis et al (2005)
28 Placebo Pain VAS SRM=7.08 (6.04 to
8.03)
NA NA NA
Naproxen Pain VAS SRM=5.43 (4.57 to
6.21)
NA NA NA
Hay et al (1999)
15 Placebo Pain VAS NA ES=1.57 (1.14 to 1.99) ES=0.00 (20.37 to 0.37) ES=0.00 (20.37 to 0.37)
Impairment of
function (10 point
Likert scale)
NA ES=0.90 (0.50 to 1.28) ES=20.22 (20.6 to 0.15) ES=0.00 (20.37 to 0.37)
Naproxen Pain VAS NA ES=2.07 (1.58 to 2.52) ES=0.41 (0.03 to 0.80) ES=0.41 (0.03 to 0.80)
Impairment of
function (10 point
Likert scale)
NA ES=1.35 (0.92 to 1.76) ES=20.45 (20.83 to
20.06)
ES=0.00 (20.38 to 0.38)
Smidt et al (2002)
29 Wait and see Pain VAS SRM=1.51 (1.09 to
1.90)
SRM=1.49 (1.08 to
1.88)
SRM=0.3 (20.06 to 0.66) SRM=20.15 (20.51 to
0.20)
Elbow disability SRM=1.45 (1.04 to
1.84)
SRM=1.46 (1.05 to
1.85)
SRM=0.10 (20.26 to
0.45)
SRM=20.36 (20.72 to
0.00)
Physiotherapy Pain VAS SRM=1.49 (1.08 to
1.87)
SRM=1.21 (0.82 to
1.58)
SRM=20.04 (20.39 to
0.31)
SRM=20.41 (20.76 to
20.05)
Elbow disability SRM=1.21 (0.82 to
1.58)
SRM=1.13 (0.74 to
1.50)
SRM=20.23 (20.58 to
0.12)
SRM=20.58 (20.93 to
20.22)
Price et al (1991)
30 Placebo Pain VAS NA ES=6.37 (4.98 to 7.58) ES=22.21 (22.85 to
21.50)
NA
Bisset et al (2006)
31 Wait and see Pain VAS ES=1.52 (1.12 to 1.90) ES=1.18 (0.80 to 1.54) ES=20.50 (20.84 to
20.15)
ES=20.64 (20.99 to
20.29)
Physiotherapy Pain VAS ES=0.99 (0.63 to 1.35) ES=0.56 (0.21 to 0.90) ES=20.81 (21.16 to
20.45)
ES=20.76 (21.11 to
20.40)
Tonks et al (2006)
12 Wait and see PREFQ-pain NA SRM=1.96 (0.88 to
2.89)
NA NA
PREFQ-function NA SRM=1.31 (0.34 to
2.17)
NA NA
Physiotherapy PREFQ-pain NA SRM=1.20 (0.18 to
2.11)
NA NA
PREFQ-function NA SRM=1.45 (0.40 to
2.38)
NA NA
Continued
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38 conducted a meta-analysis using a binary
outcome (‘‘improvement or not’’) and concluded that subacro-
mial injections of steroids are effective for improvement for
rotator cuff tendonitis up to a 9-month period, and that they
are also probably more effective than NSAIDs. Concerning
epicondylitis, Labelle et al
39 concluded that there was insuffi-
cient scientific evidence to support the use of corticosteroid
injections. In 1996, Assendelft et al
8 conducted a meta-analysis
using a binary outcome (‘‘success or failure’’). The pooled
analysis indicated short-term effectiveness of steroid injections.
However, this review differs from these earlier works in
several important respects. Firstly, it included diagnostic
considerations and attempted to differentiate studies based
upon the nature of the populations being studied, recognising
that the benefits of treatment may vary for different underlying
causes of shoulder or elbow pain. This analysis was thus centred
on tendinosis. Secondly, steroid injections were compared to
placebo but also to other commonly used treatments (‘‘wait and
see’’, NSAIDs, physiotherapy) and this heterogeneity in
comparators was taken into account, leading to sensitivity
analyses. Thirdly, effect sizes were calculated for the different
reported outcome measures in different trials. This enabled a
direct comparison between studies using the same scale,
whatever the outcome measure. If the ES could not be
calculated, another pooled measure of effect, the SRM, was
calculated when available in order not to lose information.
Fourthly, time since injections was taken into account, as
efficacy was assessed by the change in overall pain intensity
and/or physical functional status between baseline and week 1
to 3, week 4 to 8, week 12 to 24 and week 48. In spite of these
measures, statistical testing revealed heterogeneity during the
first weeks. The a priori defined sensitivity analyses showed no
changes in the main conclusions with the localisation, duration
of pain, or type of corticoid. Some other possible reasons for this
heterogeneity are variation in study quality (but only three
Jadad scores were lower than 3), differences in the type of
patients included or the composition of the various injection
fluids, variation in the number and interval of injections (four
studies allowed up to two injections and two studies up to three
injections) and different methods of outcome measurement. In
addition, diagnostic accuracy is always a difficulty in particular
for shoulder disorders: selection may have influenced the results,
as patients who were heterogeneous may have been included in
the original RCTs.
Accuracy of placement of the needle for injections may also
be an issue. Eustace et al indicated that, even in the hands of
musculoskeletal specialists, only a minority of injections for
shoulder pain are performed accurately (29% of subacromial
injections) and that outcome significantly correlates with
accuracy of injection.
40 In the present meta-analysis, radio-
graphic confirmation of appropriate needle placement and
adequate technique was carried out only on the first 10 patients
in the study by Alvarez et al.
13
Although steroid injections were more efficacious in the first
weeks than pooled comparators, importantly, steroid injections
did not demonstrate superiority in the first weeks either for pain
or for functional disability compared to NSAIDs. This is an
important finding since NSAIDs are a widely used and relatively
safe therapeutic option in tendonitis, leading to questions
regarding the role of steroid injections in these pathologies. In
usual care, steroid injections are in fact most often performed
after NSAIDs have been prescribed but without sufficient
Table 2 Continued
Reference Comparator Outcome measure Week 1–3 Week 4–8 Week 12–24 Week 48
Saartok et al
(1986)
32
Naproxen Pain score (0–8) ES=20.05 (20.90 to
0.81)
NA NA NA
Stahl et al (1997)
33 Placebo Pain VAS NA ES=3.60 (2.74 to 4.36) NA ES=1.2 (0.63 to 1.73)
Results are presented as effect (95% CI). Significant results are in bold type.
DASH, Disabilities of the Arm, Shoulder and Hand; ES, effect size; NA, not available; PREFQ, Patient Related Forearm Evaluation Questionnaire; SRM, standardised response mean;
VAS, visual analogue scale.
Figure 1 Pain standardised response
mean (SRM) at weeks 4–8 versus all
comparators.
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this meta-analysis did in fact test this treatment strategy.
Adverse clinical effects of steroid injections were system-
atically investigated in this meta-analysis. This study indicates
steroid injections are well tolerated, with infrequent and minor
side effects. The main side effect was transient pain after
injection (10.7% of corticosteroid injections). Haker et al
assumed that postinjection pain is caused by the volume effect
of the injection and the corticosteroid itself.
41 Price et al reported
a much lower percentage of postinjection pain for local
anaesthetics (11%) than for corticosteroids (50%) for the same
volume, indicating a possibly specific irritation caused by
steroids.
30 Skin atrophy and depigmentation were the second
most frequently reported side effects (4%). Although most side
effects are rare and temporary, skin atrophy and depigmenta-
tion can be permanent and should be explained to the patient
before performing an injection. Although there are clinical
reports of tendon ruptures following steroid injections,
42 43 no
study reported this adverse event. There is strong evidence to
conclude that the risks of serious adverse effects such as tendon
rupture and infections after steroid injections for the indications
andpopulations includedand withthe dosesgiven, areverysmall.
In summary, these findings suggest that injections of
corticosteroids are well tolerated and effective compared with
other commonly used treatments (wait and see, physiotherapy)
or placebo in terms of improvement of pain and function in
tendinosis (epicondylitis, rotator cuff tendonitis or subacromial
impingement) in the short term, however no long-term benefit
was shown by this meta-analysis. Moreover there appears to be
no benefit of steroid injections compared to NSAIDs. This study
may lead the doctor to systematically prescribe a course of
NSAIDs (if there are no contraindications) before potentially
performing a steroid injection. Moreover it may lead the doctor
to perform steroid injections mostly in acute or subacute
tendonitis, where the potential benefit appears clearer than in
chronic disease.
Figure 2 Function standardised
response mean (SRM) at weeks 4–8
versus all comparators.
Table 3 Pooled effect size (ES) and pooled standardised response mean (SRM) for steroid injections in tendonitis according to the comparator
Comparator Outcome Week 1–3 Week 4–8 Week 12–24 Week 48
All Pain ES 1.18 (0.27 to 2.09) 1.30 (0.55 to 2.04) 20.38 (20.85 to 0.08) 0.07 (20.60 to 0.75)
Pain SRM 2.45 (1.10 to 3.80) 0.96 (0.63 to 1.30) 0.10 (20.12 to 0.33) 20.28 (20.53 to 20.03)
Function ES 0.20 (20.30 to 0.70) 0.66 (0.03 to 1.30) 20.27 (20.49 to 20.04) 0.00 (20.27 to 0.27)
Function SRM 0.88 (0.32 to 1.44) 1.06 (0.45 to 1.66) 20.07 (20.39 to 0.25) 20.47 (20.72 to 20.22)
Placebo Pain ES 1.89 (0.20 to 3.59) 1.67 (0.56 to 2.78) 20.45 (21.01 to 0.11) 0.25 (20.82 to 1.32)
Pain SRM 2.52 (0.58 to 4.45) 1.16 (0.79 to 1.53) 0.21 (20.09 to 0.50) 20.15 (20.51 to 0.20)*
Function ES 0.20 (20.30 to 0.70)* 0.41 (20.24 to 1.07) 20.17 (20.45 to 0.11) 0.00 (20.37 to 0.37)*
Function SRM 1.08 (0.30 to 1.85) 1.57 (0.55 to 2.59) 0.09 (20.26 to 0.45)* 20.36 (20.72 to 0.00)*
Physiotherapy Pain ES 0.64 (20.18 to 1.47) 0.51 (0.19 to 0.84) 20.83 (21.18 to 20.47)* 20.74 (21.10 to 20.39)*
Pain SRM 1.48 (1.08 to 1.87)* 1.19 (0.84 to 1.55) 20.04 (20.39 to 0.31)* 20.40 (20.76,20.05)*
Function ES NE NE NE NE
Function SRM 1.20 (0.82 to 1.58)* 1.15 (0.80 to 1.51) 20.23 (20.58 to 0.12)* 20.57 (20.93 to 20.22)*
NSAID Pain ES 20.04 (20.90 to 0.82)* 0.95 (21.31 to 3.21) 0.42 (0.03 to 0.80)* 0.42 (0.03 to 0.80)*
Pain SRM 2.88 (22.64 to 8.40) 0.26 (20.16 to 0.68) NE NE
Function ES NE 1.37 (0.94 to 1.79)* 20.46 (20.84 to 20.07)* 0.00 (20.38 to 0.38)*
Function SRM 0.10 (20.45 to 0.66)* 20.04 (20.45 to 0.38) NE NE
Results are presented as effect (95% CI). Significant results are in bold type.
*One study.
NE, not estimable; NSAID, non-steroidal anti-inflammatory drug.
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Table 4 Adverse events (AE) reported for steroid injections versus placebo or other comparator
Adverse event
No (%) of AE in patients
treated with corticoids* Comparator
No (%) of AE patients treated
with comparator* NNH
All 121/713 (16.97) Placebo 34/566 (6.01) 9
Physiotherapy 80/203 (39.41) 24
NSAID 11/181 (6.08) 9
Pain 76/713 (10.66) Placebo 19/566 (3.36) 14
Physiotherapy 54/203 (26.60) 26
NSAID 0/181 (0) 9
Skin atrophy and
depigmentation
29/713 (4.07) Placebo 5/566 (0.88) 31
Physiotherapy 6/203 (2.96) 90
NSAID 0/181 (0) 25
Gastrointestinal upset 1/713 (0.14) Placebo 1/566 (0.18) 22500
Physiotherapy 0/203 (0) 714
NSAID 7/181 (3.87) 227
Facial flush 3/713 (4.21) Placebo 0/566 (0) 24
Physiotherapy 0/203 (0) 24
NSAID 0/181 (0) 24
*In studies where the AE was reported.
NNH, number needed to harm; NSAID, non-steroidal anti-inflammatory drug.
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